Market Overview - The food processing sector increased by 0.66% on October 29, with Xianle Health leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Top Gainers in Food Processing Sector - Xianle Health (300791) closed at 24.00, up 5.12% with a trading volume of 66,000 shares and a turnover of 158 million yuan [1] - Anjijia Food (603345) closed at 73.00, up 4.54% with a trading volume of 171,400 shares and a turnover of 1.243 billion yuan [1] - Kangbiter (920429) closed at 17.78, up 4.34% with a trading volume of 42,200 shares and a turnover of 71.648 million yuan [1] Top Losers in Food Processing Sector - ST Chuntian (600381) closed at 4.62, down 3.95% with a trading volume of 160,900 shares and a turnover of 74.493 million yuan [2] - Guanghong Holdings (000529) closed at 5.93, down 3.42% with a trading volume of 152,200 shares and a turnover of 90.343 million yuan [2] - Huifa Food (603536) closed at 10.86, down 2.78% with a trading volume of 104,600 shares and a turnover of 114 million yuan [2] Capital Flow Analysis - The food processing sector experienced a net outflow of 51.2618 million yuan from institutional investors, while retail investors saw a net inflow of 66.9266 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are increasing their positions [2] Individual Stock Capital Flow - Tongchen Beijian (300146) had a net inflow of 25.4486 million yuan from institutional investors, but a net outflow of 26.3022 million yuan from retail investors [3] - Shuanghui Development (000895) saw a net inflow of 6.5057 million yuan from institutional investors, while retail investors contributed a net inflow of 11.0663 million yuan [3] - Jinziham (002515) had a net inflow of 4.5988 million yuan from institutional investors, with retail investors also contributing a net inflow of 14.3141 million yuan [3]

Investment Rating - The report maintains a "Positive" investment rating for the industry [8] Core Insights - NAD+ is a crucial coenzyme involved in fundamental life processes, with its levels declining during aging, leading to increased interest in NAD+ supplements like NMN and NR for anti-aging solutions [2][4][5] - The NAD+ market is driven by the growing demand for anti-aging products, with significant players like Swisse, H&H International, and Goldenway actively participating in the sector [7][27] - Regulatory environments vary across regions, with the U.S. showing signs of loosening regulations, while China maintains strict approval processes for NAD+ related supplements [6][26] Summary by Sections NAD+ as an Important Coenzyme - NAD+ is present in all active cells and plays a role in metabolism, energy synthesis, and DNA repair [4][17] - The decline of NAD+ levels is linked to aging, making its supplementation a key focus in the health product industry [5][20] Regulatory Environment - In the U.S., there are indications of potential regulatory easing for NAD+ supplements, particularly NMN, while NR remains stable in the market [6][26] - The EU is cautiously opening up, with NR approved as a "novel food" and NMN undergoing safety assessments [6][26] - China has the strictest regulations, with no local production allowed for NMN and NR due to ongoing debates regarding their clinical efficacy [6][26] Market Players and Product Development - Key companies like Goldenway are expected to produce around 500 tons of NMN by 2025, while Swisse and other brands are launching related products [7][27] - The industry is witnessing a shift towards the commercialization of NAD+ precursors, with NR and NMN leading the way in research and product availability [5][24]

Core Viewpoint - The company, Xiamen Kingdawei Group Co., Ltd., has disclosed its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information presented [1][2]. Financial Data - The third-quarter financial report has not been audited [8]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for this quarter [3]. Shareholder Information - The company will hold its third extraordinary general meeting of 2025 on November 10, 2025, at 14:30 [9][10]. - The meeting will combine on-site voting and online voting [11]. - The record date for shareholders to attend the meeting is November 4, 2025 [12]. Meeting Agenda - The board of directors approved several proposals, including the third-quarter report and amendments to various internal management systems [26][28]. - The meeting will also address the revision of the compensation management system for directors and senior management [28]. - Other proposals include amendments to the independent director system and the external guarantee management measures, which will be submitted for shareholder approval [31][36]. Voting Process - Shareholders can participate in the voting through the Shenzhen Stock Exchange's trading system and internet voting system [20][22]. - The voting code for the meeting is 362626, and the voting will take place during specified time slots on November 10, 2025 [20][21].

Core Insights - The company reported a revenue of 875,783,445.18 yuan for the third quarter of 2025, representing a year-on-year growth of 6.89% [2] - The net profit attributable to shareholders of the listed company was 113,526,260.17 yuan, showing a year-on-year increase of 25.23% [2] Financial Performance - Revenue for Q3 2025: 875.78 million yuan, up 6.89% year-on-year [2] - Net profit for Q3 2025: 113.53 million yuan, up 25.23% year-on-year [2]

Core Insights - The company achieved a revenue of 876 million yuan in Q3 2025, representing a year-on-year growth of 6.89% [2] - The net profit attributable to shareholders was 114 million yuan, showing a year-on-year increase of 25.23% [2] - The basic earnings per share stood at 0.19 yuan [2]

Core Viewpoint - Kingdawei (002626.SZ) reported a strong performance in Q3, with significant growth in both revenue and net profit, indicating a positive trend in the company's financial health [1] Financial Performance - The company's revenue for the first three quarters reached 2.604 billion yuan, representing a year-on-year increase of 11.16% [1] - The net profit attributable to shareholders was 360 million yuan, showing a substantial year-on-year growth of 63.47% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 349 million yuan, reflecting a year-on-year increase of 56.22% [1]

Group 1 - The core point of the article is that Jindawei (SZ 002626) held its ninth board meeting on October 24, 2025, to discuss the revision of the "Board Compensation and Assessment Committee Rules" [1] - For the first half of 2025, Jindawei's revenue composition was as follows: industrial accounted for 98.5%, pharmaceutical raw materials 1.43%, and other businesses 0.07% [1] - As of the report date, Jindawei's market capitalization was 12.5 billion yuan [1] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a hot secondary market in biomedicine, while the primary market is facing fundraising challenges [1]

厦门金达威集团股份有限公司 投资者关系管理制度 第一章 总 则 第一条 为进一步完善厦门金达威集团股份有限公司(以下简称公司)治理结构， 规范公司投资者关系管理工作，根据《中华人民共和国公司法》(以下简称公司法)、 《中华人民共和国证券法》(以下简称证券法)、《上市公司投资者关系管理工作指 引》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第1 号——主板上市公司规范运作》等法律、行政法规、规章、规范性文件及公司章程 的规定，结合公司实际情况，制定本制度。 第二条 投资者关系管理是指公司便利股东权利行使、信息披露、互动交流和 诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对公司的了 解和认同，提升公司治理水平和企业整体价值，实现尊重投资者、回报投资者、保 护投资者目的的相关活动。 第三条 公司开展投资者关系管理活动，应当以已公开披露信息作为交流内容， 不得以任何方式透露或者泄露未公开披露的重大信息。 投资者关系活动中涉及或者可能涉及股价敏感事项、未公开披露的重大信息或 者可以推测出未公开披露的重大信息的提问的。 公司应当告知投资者关注公司公告，并就信息披露规则进行必要的解释 ...

第三条 本细则所称公司经理人员包括公司高级经理人和公司经理人。 (一)公司高级经理人包括：总经理、副总经理、财务总监等。 厦门金达威集团股份有限公司总经理工作细则 厦门金达威集团股份有限公司 总经理工作细则 第一章 总则 第一条 为规范公司经理人员的工作行为，保障公司经理人员依法履行职权， 根据《公司法》等有关法律、法规、规范性文件以及公司章程的规定，制定本细 则。 第二条 公司经理人员履行职权除应遵守本细则的规定外，还应符合相关法 律、法规、规范性文件和公司章程的规定。 (二)公司经理人包括：部门经理、片区经理等。 第二章 经理人员的职权范围 第四条 经理人员的职责 (一)公司经理人员应忠实履行职责，维护公司和全体股东的最大利益，并负 有下述忠实义务。同时经理人员违反本条规定所得的收入，应当归公司所有；给 公司造成损失的，应当承担赔偿责任。 (1)不得利用职权收受贿赂或者其他非法收入，不得侵占公司的财产； (2)不得挪用公司资金； (3)不得将公司资产或资金以其个人名义或者其他个人名义开立账户存储； (4)不得违反本章程的规定，未经股东会或董事会同意，将公司资金借贷给 他人或者以公司财产为他人提供担保； ( ...

厦 门 金 达 威 集 团 股 份 有 限 公 司 关 联 交 易 管 理 办 法 第一章 总则 第一条 为规范公司关联交易的决策管理和信息披露等事项，确保公司的关 联交易行为不损害公司和全体股东特别是无关联关系股东的合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》 （以下简称股票上市规则）、《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 7 号——交 易与关联交易》及其他有关法律、法规、规范性文件和本公司章程的规定，结合 公司实际，制定本办法。 第二条 公司关联交易的决策管理、信息披露等事项，应当遵守本办法。 第三条 公司处理关联交易事项应当遵循下列原则： (一)诚实信用的原则； (二)公开、公平、公正的原则； (三)依据客观标准判断的原则； (四)实质重于形式的原则。 第二章 关联人和关联关系 第四条 公司的关联人包括关联法人和关联自然人。 第五条 有下列情形之一的法人或其他组织，为公司的关联法人： (一)直接或者间接地控制公司的法人或其他组织； (二)由前项法人或组织直接或者间接控制的除本公司 ...